📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
Suven Life Sciences Allots Shares Worth ₹60 Cr on Warrant Conversion & Appoints New CS
Suven Life Sciences has approved the allotment of 44,77,612 equity shares following the conversion of fully paid warrants, raising approximately ₹60 crore. The shares were issued to 3P India Equity Fund entities at a price of ₹134 per share, increasing the total paid-up capital to 23.19 crore shares. Alongside this capital infusion, the company announced a transition in its secretarial department. Mr. Shrenik Soni has resigned as Company Secretary, and Ms. Sangeetha Laxmi Kandari, who brings over 9 years of experience, will take over the role effective February 2, 2026.
Key Highlights
Allotted 44,77,612 equity shares at an issue price of ₹134 per share (₹1 face value + ₹133 premium)
Total consideration of ₹60,00,00,008 received from 3P India Equity Fund 1 and 3P India Equity Fund 1M
Post-issue subscribed and paid-up capital increased to ₹23,19,51,819
Mr. Shrenik Soni to step down as Company Secretary and Compliance Officer on January 30, 2026
Ms. Sangeetha Laxmi Kandari appointed as the new CS and Compliance Officer effective February 2, 2026
👀 What to Watch
Investors should view the ₹60 crore fundraise as a positive liquidity event for the company's R&D-heavy business model. The immediate appointment of a successor for the Compliance Officer role indicates stable corporate governance.
Suven Life Sciences Allots 44.77 Lakh Shares on Warrant Conversion, Raising Rs 60 Crore
Suven Life Sciences has approved the allotment of 44,77,612 equity shares following the conversion of fully paid warrants. The shares were issued at a price of Rs. 134 per share, resulting in a total capital infusion of approximately Rs. 60 crore from non-promoter entities, specifically 3P India Equity Fund. This conversion increases the company's total paid-up equity share capital to 23.19 crore shares. Additionally, the company announced a change in its Key Managerial Personnel, with a new Company Secretary taking over in February 2026.
Key Highlights
Allotment of 44,77,612 equity shares at an issue price of Rs. 134 per share
Total consideration received from allottees amounts to Rs. 60,00,00,008
Primary allottees are 3P India Equity Fund 1 and 3P India Equity Fund 1M
Post-issue paid-up capital increased to 23,19,51,819 shares from 22,74,74,207 shares
Appointment of Ms. Sangeetha Laxmi Kandari as CS & Compliance Officer effective Feb 02, 2026
👀 What to Watch
Investors should view the capital infusion of Rs. 60 crore as a positive sign of institutional interest from 3P India Equity Fund. Monitor the utilization of these funds toward the company's R&D and drug discovery pipeline.
Suven Life Sciences Allots 44.77 Lakh Shares on Warrant Conversion, Raises Rs 60 Crore
Suven Life Sciences has successfully converted 44,77,612 warrants into equity shares, resulting in a capital infusion of approximately Rs 60 crore. The shares were allotted to 3P India Equity Fund entities at an issue price of Rs 134 per share, which includes a premium of Rs 133. This conversion has increased the company's total paid-up equity share capital to 23.19 crore shares. Alongside this fundraise, the company announced a transition in its compliance leadership, appointing Ms. Sangeetha Laxmi Kandari as the new Company Secretary.
Key Highlights
Allotment of 44,77,612 equity shares at an issue price of Rs 134 per share
Total capital infusion of Rs 60,00,00,008 received from non-promoter entities 3P India Equity Fund
Post-issue paid-up equity capital increased to 23,19,51,819 shares from 22,74,74,207 shares
Appointment of Ms. Sangeetha Laxmi Kandari as Company Secretary & Compliance Officer effective February 02, 2026
Resignation of outgoing Company Secretary Mr. Shrenik Soni to pursue alternate career opportunities
👀 What to Watch
Investors should view the Rs 60 crore capital infusion as a positive for the company's liquidity and balance sheet strength. Monitor the company's upcoming R&D updates to see how this capital is deployed for growth.
Suven Reaches 100% Enrollment in Ropanicant Phase-2b Trial 2 Months Ahead of Schedule
Suven Life Sciences has achieved 100% patient enrollment for its Phase-2b clinical trial of Ropanicant, a treatment for Major Depressive Disorder, more than two months ahead of schedule. The trial successfully randomized 195 patients across 35 sites in the USA within just six months of initiation. Management expects the last patient to complete the study by February 2026, with topline efficacy and safety data anticipated in May 2026. This rapid enrollment reflects strong investigator interest and accelerates the timeline for a key clinical asset.
Key Highlights
Reached 100% enrollment of 195 patients for Phase-2b Ropanicant trial in the USA.
Milestone achieved more than 2 months ahead of schedule and within 6 months of study initiation.
Last patient out (LPO) is projected for February 2026, with data readout in May 2026.
Trial evaluates efficacy via the Montgomery-Asberg Depression Rating Scale (MADRS) over 6 weeks.
Suven fully owns the intellectual property rights for Ropanicant (SUVN-911).
👀 What to Watch
Investors should monitor the stock closely leading up to the May 2026 data readout, as positive Phase-2b results would be a major valuation catalyst. However, remain aware of the high-risk nature of clinical-stage biotech investments until final efficacy is proven.
